Modified soluble FGF receptor Fc fusions with improved biological activity

Details for Australian Patent Application No. 2007326985 (hide)

Owner CENTELION

Inventors Trombe, Marc; Nesbit, Mark; Nicolazzi, Celine; Sordello, Sylvie; Cameron, Beatrice; Blanche, Francis

Agent A J Park

Pub. Number AU-A-2007326985

PCT Pub. Number WO2008/065543

Priority 07290042.6 11.01.07 EP; 06291824.8 28.11.06 EP

Filing date 28 November 2007

Wipo publication date 5 June 2008

International Classifications

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 35/00 (2006.01) Antineoplastic agents

C07K 14/15 (2006.01) Peptides having more than 20 amino acids

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C07K 14/71 (2006.01) Peptides having more than 20 amino acids

C12N 15/62 (2006.01) Mutation or genetic engineering - DNA sequences coding for fusion proteins

Event Publications

4 June 2009 PCT application entered the National Phase

  PCT publication WO2008/065543 Priority application(s): WO2008/065543

17 March 2011 Alteration of Name

  The name of the applicant has been altered to Aventis Pharma S.A.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007327004-Pyrazole analogs

2007326958-Device for detecting and signalling malfunctions in the use of electrical appliances